References
- Gardner R C, Assinder S J, Christie G, Mason G G, Markwell R, Wadsworth H, et al. Characterization of peptidyl boronic acid inhibitors of mammalian 20 S and 26 S proteasomes and their inhibition of proteasomes in cultured cells. Biochem J 2000; 346(Part 2)447–454
- Mitsiades C S, Mitsiades N, Hideshima T, Richardson P G, Anderson K C. Proteasome inhibition as a new therapeutic principle in hematological malignancies. Curr Drug Targets 2006; 7: 1341–1347, Review
- Ni H, Ergin M, Huang Q, Qin J Z, Amin H M, Martinez R L, et al. Analysis of expression of nuclear factor kappa B (NF-κB) in multiple myeloma: downregulation of NF-κB induces apoptosis. Br J Haematol 2001; 115: 279–286
- el'Agnaf M R, Ennis K E, Morris T C, Robertson J H, Markey G, Alexander H D. Successful remission induction with deoxycoformycin in elderly patients with T-helper prolymphocytic leukaemia. Br J Haematol 1986; 63: 93–104
- Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994; 12: 2588–2593
- Kipps T. Chronic lymphocytic leukemia and related disorders. Williams Hematology6th edn, E Beutler, M A Lichtman, B S Coller, T J Kipps, U Seligsohn, E Beutler, et al. McGraw-Hill, New York 2000; 1181–1182
- Goy A, Younes A, McLaughlin P, Pro B, Romaguera J E, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667–675
- O'Connor O A, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676–684
- Strauss S J, Maharaj L, Hoare S, Johnson P W, Radford J A, Vinnecombe S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006; 24: 2105–2112
- Orlowski R Z, Voorhees P M, Garcia R A, Hall M D, Kudrik F J, Allred T, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058–3065
- Mai W, Meng H, Jin J, Wang L. Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma. Eur J Haematol 2006; 77: 445–447
- Pahler J C, Ruiz S, Niemer I, Calvert L R, Andreeff M, Keating M, et al. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res 2003; 9: 4570–4577